Thyroid Cancer
Conditions
Interventions
Case group:None
Control Group:None
Sponsors
Zhujiang Hospital of Southern Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: I. Exposure Group (Women undergoing TSH-suppressive therapy after thyroid cancer surgery) 1.Aged 18–45 years (inclusive); 2.Pathologically confirmed diagnosis of thyroid carcinoma; 3.Having undergone thyroidectomy (total or partial); 4.Postoperatively initiated levothyroxine (LT4) replacement therapy, with at least 6 months of documented treatment and follow-up; 5.Absence of serious systemic diseases (e.g., uncontrolled diabetes, cardiovascular diseases); 6.Literate, voluntarily signs the informed consent form, and able to cooperate with follow-up. II. Control Group (Age-matched healthy women) 1.Aged 18–45 years (inclusive), 1:1 age-matched (+/-2 years) with the exposure group; 2.No history of thyroid disease, with normal thyroid function (TSH and FT4 within normal reference ranges); 3.No history of malignancy; 4.No known endocrine diseases affecting reproductive function (e.g., PCOS, diabetes mellitus); 5.Voluntarily signs the informed consent form and able to cooperate with follow-up.
Exclusion criteria
Exclusion criteria: I. Exposure Group (Women undergoing TSH-suppressive therapy after thyroid cancer surgery) 1.Postmenopausal women; 2.Currently pregnant or lactating; 3.Diagnosed with polycystic ovary syndrome (PCOS) or other known endocrine disorders affecting ovarian function; 4.History of other malignancies; 5.History of reproductive organ surgery (e.g., oophorectomy, hysterectomy); 6.Presence of psychiatric disorders, cognitive impairment, or expected inability to comply with long-term follow-up. II. Control Group (Age-matched healthy women) 1.Postmenopausal women; 2.Currently pregnant or lactating; 3.History of thyroid surgery or thyroid disease; 4.History of reproductive organ surgery; 5.Current use of medications that may affect reproductive endocrinology (e.g., hormonal contraceptives, ovulation induction drugs); 6.Presence of psychiatric disorders, cognitive impairment, or expected inability to comply with long-term follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti-mullerian hormone levels;Infertility; | — |
Secondary
| Measure | Time frame |
|---|---|
| Antral follicle count;Premature ovarian insufficiency;Menstrual Pattern;Pregnancy Outcome; | — |
Countries
China
Contacts
Public ContactXin Chen
Zhujiang Hospital of Southern Medical University
Outcome results
None listed